Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | HRAS |
Variant | Q61R |
Impact List | missense |
Protein Effect | loss of function |
Gene Variant Descriptions | HRAS Q61R does not lie within any known functional domains of the Hras protein (UniProt.org). Q61R results in decreased Hras GTPase activity and leads to transformation of cells in culture (PMID: 3510078). |
Associated Drug Resistance | |
Category Variants Paths |
HRAS mutant HRAS act mut HRAS Q61R HRAS mutant HRAS Q61X HRAS Q61R |
Transcript | NM_005343.4 |
gDNA | chr11:g.533874T>C |
cDNA | c.182A>G |
Protein | p.Q61R |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_005343.4 | chr11:g.533874T>C | c.182A>G | p.Q61R | RefSeq | GRCh38/hg38 |
NM_005343 | chr11:g.533874T>C | c.182A>G | p.Q61R | RefSeq | GRCh38/hg38 |
NM_001130442.3 | chr11:g.533874T>C | c.182A>G | p.Q61R | RefSeq | GRCh38/hg38 |
NM_176795.5 | chr11:g.533874T>C | c.182A>G | p.Q61R | RefSeq | GRCh38/hg38 |
NM_001130442.2 | chr11:g.533874T>C | c.182A>G | p.Q61R | RefSeq | GRCh38/hg38 |
NM_001130442 | chr11:g.533874T>C | c.182A>G | p.Q61R | RefSeq | GRCh38/hg38 |
NM_176795 | chr11:g.533874T>C | c.182A>G | p.Q61R | RefSeq | GRCh38/hg38 |
NM_176795.4 | chr11:g.533874T>C | c.182A>G | p.Q61R | RefSeq | GRCh38/hg38 |
NM_005343.3 | chr11:g.533874T>C | c.182A>G | p.Q61R | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
HRAS Q61R | Advanced Solid Tumor | sensitive | Everolimus | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing HRAS Q61R demonstrated sensitivity to growth inhibition by Afinitor (everolimus) in culture (PMID: 26544513). | 26544513 |
HRAS Q61R | Advanced Solid Tumor | sensitive | Binimetinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing HRAS Q61R demonstrated sensitivity to growth inhibition by Binimetinib (MEK162) in culture (PMID: 26544513). | 26544513 |
HRAS Q61R | bladder urothelial carcinoma | predicted - sensitive | Tipifarnib | Case Reports/Case Series | Actionable | In a Phase II trial, Zarnestra (tipifarnib) demonstrated manageable toxicity profile, resulted in an objective response rate of 33.3% (5/15) in patients with transitional cell carcinoma harboring HRAS mutations, 2 patients with bladder urothelial carcinoma harbored HRAS Q61R achieved partial responses (PMID: 32636318; NCT02535650). | 32636318 |